IMM2902, a novel bispecific antibody, simultaneously targets CD47 and HER2, significantly enhancing anti-tumor immune responses by blocking the CD47/SIRPα signaling pathway and activating immune cell phagocytosis. Here, ERBB2 is linked to neoplasm.